anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ZAROXOLYN (metolazone) is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. The actions of ZAROXOLYN result from interference with the renal tubular mechanism of electrolyte reabsorption. ZAROXOLYN acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. ZAROXOLYN does not inhibit carbonic anhydrase. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies.

When ZAROXOLYN Tablets are given, diuresis and saluresis usually begin within one hour and may persist for 24 hours or more. For most patients, the duration of effect can be varied by adjusting the daily dose. High doses may prolong the effect. A single daily dose is recommended. When a desired therapeutic effect has been obtained, it may be possible to reduce dosage to a lower maintenance level.

The diuretic potency of ZAROXOLYN at maximum therapeutic dosage is approximately equal to thiazide diuretics. However, unlike thiazides, ZAROXOLYN may produce diuresis in patients with glomerular filtration rates below 20 mL/min.

ZAROXOLYN and furosemide administered concurrently have produced marked diuresis in some patients where edema or ascites was refractory to treatment with maximum recommended doses of these or other diuretics administered alone. The mechanism of this interaction is unknown (see and ). WARNINGSPRECAUTIONS, Drug Interactions

Maximum blood levels of metolazone are found approximately eight hours after dosing. A small fraction of metolazone is metabolized. Most of the drug is excreted in the unconverted form in the urine.
Participants and Methods: A pilot study is conducted by comparing the change in skin surface temperature before and after using sham or tonifying or dispersing acupuncture manipulations at EX-B2 T3 in right side and Dazhui in heatlhy volunteers. A total of 57 participants will be randomly divided into 3 groups (group STD, group TDS and group DST). Each group has 19 participants and undergo 3 trial phases, corresponding to 3 times of acupuncture in 14 days, each time is 7 days apart. For group STD, the first trial phase: participants received acupuncture at EX-B2 T3 point in right side as sham acupuncture; the second trial phase: participants received acupuncture with tonifying manipulations at Dazhui point and tonifying manipulations was replaced by dispersing ones in the third trial phase. For group TDS, the first trial phase: participants received acupuncture with tonifying manipulations at Dazhui point; the second trial phase: participants received acupuncture with dispersing manipulations at Dazhui point and participants received acupuncture at EX-B2 T3 point in right side as sham acupuncture in the third trial phase. Similarly, for group DST, the first trial phase: participants received acupuncture with dispersing manipulations at Dazhui point; the second trial phase: participants received acupuncture at EX-B2 T3 point in right side as sham acupuncture and sham acupuncture was replaced byacupuncture with tonifying manipulations at Dazhui in the third trial phase. The primary outcome was the change temperature of skin surface at the acupuncture site, the neck and the face when using tonifying or dispersing acupuncture manipulations at Dazhui point. This trial will be performed as a pilot study.
Inactivity can lead to muscle atrophy and capillary regression in skeletal muscle. Niacin (NA), known for inducing hypermetabolism, may help prevent this capillary regression. In this study involving adult female Sprague-Dawley rats, the animals were randomly assigned to one of four groups: control (CON), hindlimb unloading (HU), NA, and HU with NA supplementation (HU + NA). For a period of 2 weeks, the rats in the HU and HU + NA groups underwent HU, while those in the NA and HU + NA groups received NA (750 mg/kg) twice daily through oral administration. The results demonstrated that HU lowered capillary number, luminal diameter, and capillary volume, as well as decreased succinate dehydrogenase activity, slow fiber composition, and PGC-1α expression within the soleus muscle. However, NA supplementation prevented these alterations in capillary structure due to unloading by stimulating PGC-1α factors and inhibiting mitochondrial dysfunction. Therefore, NA supplementation could serve as a potential therapeutic approach for preserving the capillary network and mitochondrial metabolism of muscle fibers during periods of inactivity.
The Symax hip stem is an uncemented design forged from Ti6Al4V alloy (Stryker EMEA). Primary mechanical stability is provided by anatomical metaphyseal geometry. The hip stem features a size dependent anteversion, neck length and offset, with a CCD angle of 128°. Secondary biological stability is accomplished by fast osseous integration due to the BONIT-HA coating on the metaphyseal part of the stem.
PURPOSE: To obtain the subject cosmetic excellent in foamability during hair washing therewith, and also excellent in both the coherency and dry touch feeling of the hair after washed therewith. CONSTITUTION: This cosmetic contains, as active ingredients, 0.1-3wt.% of a specific silicone-modified polymer and an anionic surfactant (e.g. an α- acylsulfonic acid salt) and/or an amphoteric surfactant (e.g. a carboxybetaine type one). The silicon-modified polymer is prepared by reaction between an amino group-contg. polysiloxane of the formula (A is OH, an alkoxyl or amino- contg. alkyl; R is a 1-18C alkyl or OH; Q is an amino-contg. alkyl; (m) and (n) are each 0-3; (x) is 30-400; (y) is 1-3) and an anionic polymer followed by neutralizing the reaction product with an alkaline compound so as to be 60-150% in neutralization degree. This cosmetic can be prepared into the form of shampoo, rinse, treatment or hair grooming agent by appropriately incorporating conventional hair-washing cosmetic ingredients in addition to the above active ingredients.
The recommended starting dosage of DHIVY is one 25 mg / 100 mg tablet taken orally three times a day. This dosage schedule provides 75 mg of carbidopa per day. Dosage may be increased by up to one whole tablet every day or every other day, as needed to a maximum daily dosage of eight whole tablets.

Dosing with DHIVY should be individualized and adjusted according to clinical response and tolerability. The tablet is functionally scored to facilitate dose adjustment. At least 70 mg to 100 mg of carbidopa per day should be provided. Experience with total daily dosages of carbidopa greater than 200 mg is limited.

Monitor patients closely during the dose adjustment period. Specifically, involuntary movements may occur with DHIVY, which may require dosage reduction. Blepharospasm may be a useful early sign of excess dosage in some patients.

Maintain patients on the lowest dosage required to achieve symptomatic control and to minimize adverse reactions, such as dyskinesia and nausea.
A computer-implemented method, computer program product, and computing system for visual diarization of a user encounter is executed on a computing device and includes obtaining encounter information of the user encounter. The encounter information is processed to: associate a first portion of the encounter information with a first encounter participant, and associate at least a second portion of the encounter information with at least a second encounter participant. A visual representation of the encounter information is rendered. A first visual representation of the first portion of the encounter information is rendered that is temporally-aligned with the visual representation of the encounter information. At least a second visual representation of the at least a second portion of the encounter information is rendered that is temporally-aligned with the visual representation of the encounter information.A computer-implemented method, computer program product, and computing system for visual compartmentalization of a user encounter is executed on a computing device and includes obtaining encounter information of the user encounter. The encounter information is processed to: associate a first portion of the encounter information with a first encounter portion, and associate at least a second portion of the encounter information with at least a second encounter portion. A visual representation of the encounter information is rendered. A first visual representation of the first portion of the encounter information is rendered that is temporally-aligned with the visual representation of the encounter information. At least a second visual representation of the at least a second portion of the encounter information is rendered that is temporally-aligned with the visual representation of the encounter information.A computer-implemented method, computer program product, and computing system for reactive encounter scanning is executed on a computing device and includes obtaining encounter information of a user encounter. A request is received from a user concerning a specific condition. In response to receiving the request, the encounter information is processed to determine if the encounter information is indicative of the specific condition and to generate a result set. The result set is provided to the user.A computer-implemented method, computer program product, and computing system for proactive encounter scanning is executed on a computing device and includes obtaining encounter information of a user encounter. The encounter information is proactively processed to determine if the encounter information is indicative of one or more conditions and to generate one or more result sets. The one or more result sets are provided to the user.
What is this summary about?This plain language summary shares results from a clinical study called INTEGRIS-IPF that was published in the American Journal of Respiratory and Critical Care Medicine in 2024. This study looked at a medicine called bexotegrast (beck-so-teh-grast) as a possible treatment for idiopathic pulmonary fibrosis (i-dee-uh-pa-thick pul-muh-ner-ee fie-bro-sis; IPF). Bexotegrast is an investigational medicine, which means that it is being studied and has not yet been approved by the US Food and Drug Administration (FDA), for people with IPF to take as a treatment. IPF is a chronic, progressive lung disease that makes it hard to breathe and gets worse over time. There is no cure for IPF, treatment includes symptom management and consideration for the use of nintedanib or pirfenidone, which may decrease the pace of disease progression.The study compared bexotegrast to a placebo (a treatment that looks identical to the medicine but has no medicinal effect) to look at how well it works and how safe it is in treating people with IPF. Most people in the study also took one of two medicines that are already approved by the FDA for IPF, pirfenidone or nintedanib.
This is a cross-sectional descriptive study with a research/action design to be carried out at the Consorci Corporació Sanitària Parc Taulí (CCSPT). The aim of this study is to identify the knowledge that CCSPT nurses have in relation to care aimed at coping with anxiety, fear or loneliness and the use that they have made of it in the recent crisis. By its design, the research/action will allow the training of these nurses to improve nursing care of these aspects in the future. This is a population-based study, in which all CCSPT nurses who have carried out care work during the COVID-19 crisis period will be invited to participate. The variables collected will be age, sex, academic level, usual work shift, care given to reduce anxiety, fear, loneliness, coping style and self-pity. Quantitative variables will be described by their mean and standard deviation, while qualitative variables will be described in absolute and relative frequencies. A linear or non-parametric correlation will be made between the score on the self-pity and coping scales and the number of actions identified and/or performed referred to by the nurses and the calculation of the Pearson or Spearman correlation coefficient, as appropriate. Comparison of the number of actions between high activity and low activity (70% cut) coping nurses using the Mann-Whitney U test
OBJECTIVES: Blood transfusion plays a crucial role in coronary artery bypass grafting (CABG). The choice between autologous cell saver (CS) and allogenic blood transfusion (ABT) has been a continuous debate in the medical community, especially within cardiac surgery. This study aimed to assess the outcomes of off-pump CABG (OPCAB) surgery in patients receiving blood solely via cell salvage compared to those receiving ABT or a combination of ABT and CS perioperatively.
METHODS: A total of 414 patients who underwent isolated OPCAB surgery at our cardiovascular clinic were analyzed. Among them, 250 patients (60.4%) received blood via CS alone, while 164 patients (39.6%) received either ABT or a mix of ABT and CS. Stabilized inverse probability treatment weighted (IPTW) matching technique ensured balance in baseline covariates.
RESULTS: We found no significant differences in 30-day mortality rates between the CS and ABT groups. The CS group displayed significantly lower rates of overall complications, encompassing stroke, acute kidney injury, atrial fibrillation, and pulmonary complications. Rates of sepsis, readmission, gastrointestinal complications, heparin-induced thrombosis, and deep venous thrombosis were comparable between the two groups. However, in contrast to the ABT group, the CS group exhibited significantly shorter median lengths of hospital stay (LOHS), ICU stay, and ventilation time, along with higher rates of discharge to home rather than acute care facilities.
CONCLUSION: Our data suggest that autologous blood transfusion via CS results in fewer perioperative complications and faster recovery following OPCAB procedures as compared to ABT.
Participants receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks. Beginning 2 weeks before the assigned quit date, participants receive a Walking Program guide and engage in the SCwPA comprising brisk, self-paced walking with a goal of 150 minutes of exercise activity per week for 5 weeks.
Patients will have a superficial electrode circuit placed over the belly of the tibialis anterior muscle. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.
Pain is a distinctive burden in atopic dermatitis and recognized as an important and highly prevalent symptom. It is unknown if the presence of atopic disease may sensitize children to adverse pain profiles in the long term. We aimed to assess the impact of early-life atopic dermatitis-like symptoms on pain at 10 years of age. We used data from 1302 and 874 participants of the Generation XXI birth cohort evaluated at 6 and 15 months, respectively, and 10 years. Atopy-like symptoms since birth, including atopic dermatitis, were collected at ages 6 and 15 months by interviewing parents. Pain history in the last 3 months at age 10 was collected from parents and children using structured questionnaires. We computed relative risks (RR) and respective 95% confidence intervals of pain features at age 10 according to each atopic-like symptom at 6 and 15 months. Children whose parents reported atopic dermatitis-like symptoms at 6 months and at 15 months had higher risk of reporting any pain (RR 1.75 [1.15-2.66]) and multisite pain, respectively (RR 1.67 [1.18-2.37]) at 10 years of age.  Conclusion: Atopic dermatitis symptoms in early life were associated with a higher risk of pain at age 10, suggesting that potential for sensitization during the first decade of life and highlighting the importance of improving the health care of children with atopic dermatitis is worth investigating. What is Known: • Atopic disorders have been associated with many non-atopic comorbidities, including chronic pain. • Pain and atopic dermatitis share common inflammatory pathways. Inflammation, injury to the skin from scratching, fissures, and intolerance to irritants related to atopic dermatitis can cause pain. What is New: • Atopic dermatitis in early life is linked to an increased likelihood of experiencing pain at the age of 10, which suggests that exploring the potential for sensitization is a worthwhile area of investigation. • Our proof-of-concept study highlights the potential benefit of studying management targets and improving itching and relieving skin pain as quickly as possible, avoiding potential long-term consequences of the sensitization process.
Amuc_1100 is a membrane protein from Akkermansia muciniphila, which has been found to play a role in host immunological homeostasis in the gastrointestinal tract by activating TLR2 and TLR4. In this study we investigated the effects and underlying mechanisms of Amuc_1100 on acute pancreatitis (AP) induced in mice by intraperitoneal injection of caerulein and lipopolysaccharide (LPS). The mice were treated with the protein Amuc_1100 (3 μg, i.g.) for 20 days before caerulein injection. Cecal contents of the mice were collected for 16S rRNA sequencing. We found that pretreatment with Amuc_1100 significantly alleviated AP-associated pancreatic injury, reduced serum amylase and lipase. Amuc_1100 pretreatment significantly inhibited the expression of proinflammatory cytokines (TNF-α, IL-1β, IFN-γ and IL-6) in spleen and pancreas through inhibiting NF-κB signaling pathway. Moreover, Amuc_1100 pretreatment significantly decreased the inflammatory infiltration, accompanied by the reduction of Ly6C+ macrophages and neutrophils in the spleen of AP mice. Gut microbiome analysis showed that the abundance of Bacteroidetes, Proteobacteria, Desulfobacterota and Campilobacterota was decreased, while the proportion of Firmicutes and Actinobacteriota was increased in AP mice pretreated with Amuc_1100. We further demonstrated that Amuc_1100 pretreatment restored the enrichment of tryptophan metabolism, which was mediated by intestinal flora. These results provide new evidence that Amuc_1100 lessens the severity of AP through its anti-inflammatory properties with a reduction of macrophages and neutrophil infiltration, as well as its regulation of the composition of intestinal flora and tryptophan metabolism.
1,242,211. Powder compositions for inhalation. FISONS PHARMACEUTICALS Ltd. 23 July, 1968 [8 Aug., 1967], No. 36270/67. Heading A5B. A pharmaceutical powder composition for inhalation comprises a mixture of a solid finely divided medicament having an effective particle size in the range 0.01 to 10 microns and a solid pharmaceutically acceptable water-soluble carrier having an effective particle size in the range 30-80 microns. The composition is preferably substantially free of particles having effective particle sizes in the range 11-29 microns. The medicament may be diluted with a solid pharmaceutically acceptable watersoluble diluent of the same effective particle size. The diluent or carrier may be dextran, mannitol or lactose preferably crystalline lactose. The medicament may be an antianaphylactic agent such as sodium chromoglycate, a sympathomimetic amine such as isoprenaline or ephedrine, an antibiotic such as penicillin or tetracycline, a steroid, enzyme, vitamin, antihistamine or mucolytic such as N- acetyl cysteine. A preferred composition contains sodium chromoglycate and isoprenaline sulphate. The surface characteristics of the medicament or carrier particles may have been modified by crystallisations, spray drying, precipitation or by coating with a pharmaceutically acceptable material, e.g. stearic acid or polyvinyl pyrrolidone (which coating may give the medicament sustained release action). The powder may be contained in a capsule, e.g. of gelatin or plastic, which is pierced for administration. The powder may be administered as a dispersion in an air stream obtained by simultaneous rotation and vibration of the pierced capsule. The composiitons are prepared by mixing together, preferably in a stirred mixer, the medicament and carrier, which if necessary have been subjected to comminution and particle size classification prior to mixing.
[GB1242211A]
Up to thirty adults with bilateral, moderate stage idiopathic PD will be enrolled in this longitudinal study. Participants will serve as their own control, receiving alternating active and sham therapy at two-month intervals. This longitudinal protocol will be open-ended to enable continued treatment to those interested / motivated.

Study treatment will consist of daily, four-hour vibrotactile Coordinated Reset (vCR) stimulation sessions on a continual basis. All daily vCR stimulation sessions will occur at the participant's home (ON-medication) and can be broken up into two, two-hour blocks (with no more than 12 hours between stimulation blocks) to be less cumbersome and better integrate into the participant's daily life. Daily home-based treatment will be unsupervised, though timely support is guaranteed by Synergic Medical Technologies (SMT) support staff when needed (e.g., when usability or IT issues arise). Daily stimulation / device usage will be automatically logged by the device and continuously monitored by SMT staff, meanwhile participants will keep a med diary so we can monitor their med usage (and how it relates to extended exposure) over time. Participants will be able to transition to an as-needed basis with treatment after four months and once they are familiar with the treatment and their body's response to it, to better alleviate PD symptoms.
Human insulin analogs are disclosed. These analogs are tissue-selective. Accordingly, pharmaceutical formulations containing the analogs of the invention provide superior clinical benefits as compared to human insulin when used in the treatment of patients suffering from diabetes. The analogs are modified at amino residue A12, A15 or A19, are different from the naturally occurring residue at said position, and are hepatoselective. Also disclosed are human insulin analogs modified at amino acid residues A12 or A14 or amino acids residues A10 and A13, different from naturally occurring residues or residues at said position or positions and peripheral selective. DNA sequences and microorganisms comprising sequences coding for human insulin analogs are also provided. Processes for preparing the human insulin analogs are described.
The invention relates to a Chinese medicine tincture for treating rheumatoid arthritis for external use. By observation of patient with the rheumatoid arthritis, research in pathology and medicinal experiments of many years, prescript to of the medicine is formed based on an ancestral secret prescriptions in such a way that the medicine is combined by Chinese medicines of muskiness, borneol, camphor, whole worm liquid and the like. The chinese medicine tincture for external use has remarkable and rapid curative effect which has been clinically used for decades. The main advantages of the rheumatic oil are in that: it has strong penetrability, capability of promoting blood circulation by removing blood stasis and good detumescence analgesic effect, which can not only treat the rheumatoid arthritis, but has a certain curative effect for dermatitis, conjunctivitis, keratitis, parotitis, faucitis, toothache and other inflammatory pain, ermatosis, carbuncle, mosquito bites and strain of lumbar muscles, yperosteogeny, bone fracture and sprain. Internal diseases of gastric cancer, liver cancer and esophagus cancer can also be externally treated by the tincture in large dosage as a certain releasing function. It is proved by patients in decades that the cure rate is 100%, thus the medicine may be requisite in a household.